When AbbVie wrote a $1.2 billion cheque for Gilgamesh Pharmaceuticals’ Bretisilocin, it wasn’t just buying a drug, it was buying a future. That future, once dismissed as fringe science, is now being reframed as one of the most promising frontiers in modern psychiatry: psychedelic-inspired therapeutics that heal the brain not through serotonin tweaks, but by rebuilding neural architecture itself.
